Biora Therapeutics, Inc. BIORQ
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -- | -184.88% | -4.36% |
| Total Depreciation and Amortization | -- | -- | -- | -51.71% | -46.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -20.65% | 5.36% |
| Total Other Non-Cash Items | -- | -- | -- | 363.07% | 11.37% |
| Change in Net Operating Assets | -- | -- | -- | 302.49% | 134.59% |
| Cash from Operations | -- | -- | -- | 46.05% | 51.02% |
| Capital Expenditure | -- | -- | -- | 95.33% | 84.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 96.72% | 80.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | 43.37% | -79.40% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 310.82% | 221.67% |
| Cash from Financing | -- | -- | -- | 131.06% | -71.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -- | 69.06% | -38.90% |